Eagle Pharmaceuticals

263 articles with Eagle Pharmaceuticals

• Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results

  3/13/2023

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and 12 months ended December 31, 2022.

• Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference

  3/9/2023

  Eagle Pharmaceuticals, Inc. will participate in a fireside chat at the Barclays Global Healthcare Conference, in Miami, FL.

• Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023

  3/3/2023

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its fourth quarter and full year 2022 financial results on Monday, March 13, 2023, before the market opens.

• Eagle Pharmaceuticals Provides Business Update and Guidance for 2023

  1/10/2023

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided a business update and guidance for 2023.

• Eagle Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference

  12/21/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference.

• Eagle Pharmaceuticals Receives FDA Approval for Additional Indication for PEMFEXY® in Combination with Pembrolizumab and Platinum Chemotherapy

  12/19/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has approved an additional indication for PEMFEXY® (pemetrexed injection) in combination with pembrolizumab and platinum chemotherapy for the initial treatment of patients with metastatic, non-squamous, non-small cell lung cancer (“NSCLC”) with no EGFR or ALK genomic tumor aberrations.

• Eagle Pharmaceuticals Reaches Settlement Agreement with Accord Healthcare, Inc. Related to BENDEKA® (bendamustine hydrochloride)

  12/12/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it has reached a settlement agreement with Accord Healthcare, Inc. (“Accord”).

• Eagle Pharmaceuticals’ Investor Day to Focus on Acute Care Products and Pipeline Programs; Tuesday, December 6, 2022, at 8:00am ET at the Lotte New York Palace

  12/1/2022

  Eagle Pharmaceuticals, Inc. today announced that the following distinguished Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace, at 8:00am ET.

• Eagle Pharmaceuticals’ Investor Day to Feature World-Renowned KOLs on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

  11/16/2022

  Eagle Pharmaceuticals, Inc. today announced that the following speakers and world-renowned Key Opinion Leaders will be featured at the Company’s Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET.

• Eagle Pharmaceuticals Announces FDA Acceptance of Investigational New Drug Application for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Adjunct Treatment of Severe Community-Acquired Bacterial Pneumonia

  11/14/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) announced today that the U.S. Food and Drug Administration (“FDA”) has accepted its investigational new drug (“IND”) application for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the adjunct treatment of severe community-acquired bacterial pneumonia (“SCABP”).

• Correcting & Replacing: Eagle Pharmaceuticals Reports Third Quarter 2022 Results

  11/9/2022

  Eagle Pharmaceuticals, Inc. is re-issuing in its entirety its earnings press release for the third quarter ended September 30, 2022, originally issued on November 7, 2022 at 6:50 am ET, to correct errors in the presentation of certain line items in the financial statements included therein and corresponding references to such items in the narrative disclosure as described in the Company's Form 8-K/A filed on November 9, 2022.

• Eagle Pharmaceuticals Reports Third Quarter 2022 Results

  11/7/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2022.

• Eagle Pharmaceuticals to Host Third Quarter 2022 Financial Results on November 7, 2022

  10/31/2022

  Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2022 third quarter financial results on Monday, November 7, 2022, before the market opens.

• SAVE THE DATE: Eagle Pharmaceuticals to Host Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel

  10/19/2022

  Eagle Pharmaceuticals, Inc. announced that the Company will host an Investor Day on Tuesday, December 6, 2022, at the Lotte New York Palace Hotel, at 8:00am ET.

• 

  FDA Review: Phanes, Pfizer, GSK and More

  10/14/2022

  The FDA has numerous activities and interactions with Phanes, Prestige Biopharma, Reata, Pfizer and more, providing clearance, approving clinical trials and other regulatory actions.  

• Eagle Pharmaceuticals Announces Submission of Investigational New Drug Application to U.S. FDA for CAL02, a Novel First-in-Class Broad-Spectrum Anti-Virulence Agent for the Treatment of Severe Community-Acquired Bacterial Pneumonia

  10/12/2022

  Eagle Pharmaceuticals, Inc. announced today that it has submitted an investigational new drug application to the U.S. Food and Drug Administration for CAL02, a novel first-in-class broad-spectrum anti-virulence agent for the treatment of severe community-acquired bacterial pneumonia.

• 

  FDA Review: Alnylam, Cytokinetics, Eli Lilly and More

  10/7/2022

  The FDA had a fairly quiet week, approving drugs, providing clearance, greenlighting clinical trials, and other regulatory activities for Alnylam, Eli Lilly, Cytokinetics, and more.

• Eagle Pharmaceuticals and Enalare Therapeutics Announce FDA Orphan Drug Designation for ENA-001 for the Treatment of Apnea of Prematurity, a New Chemical Entity Being Developed as an Agnostic Respiratory Stimulant

  10/3/2022

  Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. (“Enalare”) today announced that the U.S. Food and Drug Administration (“FDA”) has granted Orphan Drug Designation (“ODD”) to ENA-001 for the treatment of Apnea of Prematurity (“AoP”), a new chemical entity with a novel mechanism of action as a respiratory stimulant.

• Eagle Pharmaceuticals and Enalare Therapeutics Announce Additional Award Worth Up to $50 Million from BARDA to Advance an Intramuscular (“IM”) Formulation of ENA-001

  9/27/2022

  Eagle Pharmaceuticals, Inc. and Enalare Therapeutics Inc. announced that Enalare has secured a contract for up to $50.3 million from the Biomedical Advanced Research and Development Authority, part of the Administration for Strategic Preparedness and Response in the U.S. Department of Health and Human Services.

• Eagle Pharmaceuticals to Present at the Morgan Stanley 20th Annual Global Healthcare Conference

  8/30/2022

  Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the Morgan Stanley 20th Annual Global Healthcare Conference.